BibTex format

author = {Bowtell, DD and Boehm, S and Ahmed, AA and Aspuria, P-J and Bast, RC and Beral, V and Berek, JS and Birrer, MJ and Blagden, S and Bookman, MA and Brenton, JD and Chiappinelli, KB and Martins, FC and Coukos, G and Drapkin, R and Edmondson, R and Fotopoulou, C and Gabra, H and Galon, J and Gourley, C and Heong, V and Huntsman, DG and Iwanicki, M and Karlan, BY and Kaye, A and Lengyel, E and Levine, DA and Lu, KH and McNeish, IA and Menon, U and Narod, SA and Nelson, BH and Nephew, KP and Pharoah, P and Powell, DJ and Ramos, P and Romero, IL and Scott, CL and Sood, AK and Stronach, EA and Balkwill, FR},
doi = {10.1038/nrc4019},
journal = {Nature Reviews Cancer},
pages = {668--679},
title = {Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer},
url = {},
volume = {15},
year = {2015}

RIS format (EndNote, RefMan)

AB - High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.
AU - Bowtell,DD
AU - Boehm,S
AU - Ahmed,AA
AU - Aspuria,P-J
AU - Bast,RC
AU - Beral,V
AU - Berek,JS
AU - Birrer,MJ
AU - Blagden,S
AU - Bookman,MA
AU - Brenton,JD
AU - Chiappinelli,KB
AU - Martins,FC
AU - Coukos,G
AU - Drapkin,R
AU - Edmondson,R
AU - Fotopoulou,C
AU - Gabra,H
AU - Galon,J
AU - Gourley,C
AU - Heong,V
AU - Huntsman,DG
AU - Iwanicki,M
AU - Karlan,BY
AU - Kaye,A
AU - Lengyel,E
AU - Levine,DA
AU - Lu,KH
AU - McNeish,IA
AU - Menon,U
AU - Narod,SA
AU - Nelson,BH
AU - Nephew,KP
AU - Pharoah,P
AU - Powell,DJ
AU - Ramos,P
AU - Romero,IL
AU - Scott,CL
AU - Sood,AK
AU - Stronach,EA
AU - Balkwill,FR
DO - 10.1038/nrc4019
EP - 679
PY - 2015///
SN - 1474-175X
SP - 668
TI - Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
T2 - Nature Reviews Cancer
UR -
UR -
UR -
VL - 15
ER -